Question Bank › New business is being written on visibly better

New business is being written on visibly better terms than the company's own recent norm, and the mix shift…

New business is being written on visibly better terms than the company's own recent norm, and the mix shift has just beg

Calls Tested
496
Answered YES
13
Hit Rate
2.6%
rare by design

Akoya Biosciences, Inc. (AKYA) — this company's answers

NO on the Q2 2023 call 2023-08-07 C+
The model's full reasoning — Q2 2023 call → NOWe need to determine if management indicates that the economic terms of the newest business have stepped up meaningfully above the company's own recent norm, and that this improvement has only begun to flow into reported results because most of the business in the reported numbers was still written at older, less favorable terms. Let's analyze the transcript. The question is about economic terms: prices, rates, fees, spreads, contract sizes, durations, or profitability. The context is a spatial biology company selling instruments and reagents. The "economic terms" could refer to pricing of instruments, reagent pull-through (revenue per instrument), contract sizes, etc. Management discusses reagent pull-through: "annualized second quarter reagent pull-through has now increased to the mid-$30,000 range for both the PhenoCycler and HT as more PhenoCyclers paired with Fusion are up and running and as we see increasing utility of HT among biopharma and CROs, which are also our target customers for the recently launched PhenoCode signature panels. This is compared to an annualized pull-through per instrument in 2022 in the low $30,000 range for both the PhenoCycler and the PhenoImager HT." So pull-through increased from low $30k to mid $30k. That's an improvement in economics per instrument. But is that a "meaningful step up"? It's a modest increase. Also, they say "we anticipate annual reagent revenue growth to be in this range for the next several years." That suggests they expect continued growth. But the question specifically asks about "the economic terms of the company's newest business" — meaning the deals, orders, contracts, renewals, or transactions being struck now. The pull-through is a measure of reagent revenue per instrument, which reflects utilization and reagent consumption. It's not exactly pricing per unit, but it's a measure of revenue per instrument. However, the question is about "prices, rates, fees, spreads, contract sizes, durations, or profitability." Pull-through is a combination of volume and price. But management doesn't explicitly say they are raising prices or that new contracts are at better terms. They mention new product launches like signature panels and discovery panels, which might have higher ASPs. But they don't explicitly state that the terms of new business are meaningfully better than recent norm.

← Back to the full AKYA analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management indicate that the ECONOMIC TERMS OF THE COMPANY'S NEWEST BUSINESS — the prices, rates, fees, spreads, contract sizes, durations, or profitability at which its most recent deals, orders, contracts, renewals, or transactions are being struck — have stepped up MEANINGFULLY ABOVE THE COMPANY'S OWN RECENT NORM, and that this improvement in the terms of incoming business has only BEGUN to flow into the reported results, because most of the business in the reported numbers was still written at the older, less favorable terms? Answer YES when management's own words convey BOTH halves of this one phenomenon, in whatever form fits the industry: (1) THE TERMS OF NEW BUSINESS HAVE VISIBLY IMPROVED VERSUS THE COMPANY'S OWN RECENT PAST. Management describes the transactions the company is signing, booking, or renewing NOW as carrying meaningfully better economics than what the same kind of business fetched in the company's own recent experience — for example: new contracts, charters, leases, policies, loans, or engagements being written at higher rates, prices, or spreads than those they replace; renewals or repeat orders coming in at clearly better levels than the expiring ones; recent deals notably larger, longer, or richer than the company's own norm; or the profitability of newly won work described as a step above the book it is joining. The comparison must be against the company's OWN recent terms (not against competitors or the industry), and the better terms must be described as ACTUALLY BEING ACHIEVED on real, current transactions — signed, booked, or closed — not merely targeted, quoted, hoped for, or dependent on future market moves. (2) THE REPORTED RESULTS STILL MOSTLY REFLECT THE OLD TERMS. Management conveys, directly or plainly in substance, that the improvement is early in the numbers: the reported period is still dominated by business struck at the earlier terms, the better-terms transactions are only a small or growing share of the mix, or results are expected to improve as the newer terms naturally become a larger portion of the business over coming periods — without requiring new demand, market recovery, or events not yet secured. Answer NO if better pricing is described mainly as passing through the company's own cost increases (inflation, freight, materials, wages, currency) rather than a genuine step-up in the economics of the business. NO if improved terms are only planned, targeted, quoted, or expected from future market conditions rather than already achieved on real transactions. NO if management describes pricing or terms as flat, competitive, under pressure, or deteriorating. NO if the improvement is attributed chiefly to a one-time deal, a temporary spike, or conditions management itself expects to reverse. NO if the better terms are already fully reflected in the reported results, with no meaningful mix shift still ahead. NO if the idea appears only in an analyst's question or model that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CTO CTO Realty Growth, Inc. Q2 2023 2023-07-28 B
CARS Cars.com Inc. Q1 2023 2023-05-06 B
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
CRBG Corebridge Financial, Inc. Q4 2022 2023-02-22 B
FLR Fluor Corporation Q2 2022 2022-08-05 D
CRL Charles River Laboratories International Q2 2022 2022-08-03 C
BRKL Brookline Bancorp, Inc. Q2 2022 2022-07-30 B+
INVH Invitation Homes Inc. Q2 2022 2022-07-28 B+
MTB M&T Bank Corporation Q2 2022 2022-07-20 B+
GFS GLOBALFOUNDRIES Inc. Q3 2021 2021-11-30 A
GNK Genco Shipping & Trading Limited Q2 2021 2021-08-07 A
ESS Essex Property Trust, Inc. Q2 2018 2018-08-03 B+
ALLY Ally Financial Inc. Q1 2018 2018-04-26 B+

How the model reasoned

CRL · Q2 2022 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...YES Management's comments on Safety Assessment pricing and backlog directly address both required elements: they describe current bookings and backlog at "escalating prices" and "meaningful price increases" that are already achieved on real transactions (not targets or future expectations), while noting that the reported Q2 results are still dominated by older 2022 terms and that the stronger pricing is accelerating into H2 and 2023 bookings.
ESS · Q2 2018 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...YES Management describes the loss-to-lease metric rising to 3.
CTO · Q2 2023 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...

More from the question bank

Quarter of firsts: the period's story is buiPriced for one buyer, wanted by manyAlready inside the gateCostly self-restriction to protect one part Losses shrinking while the business growsUncontested runwayAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.